Skip to main content

Table 1 Patients, disease and treatment characteristics

From: Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view

 

WT KRAS (n = 964)

KRAS mutation (n = 658)

p-value

Male, n (%)

593 (61.5)

405 (61.6)

0.999

Age at bevacizumab treatment initiation, median, (min-max)

61 yrs (22–85)

63 yrs (22–83)

<0.001

Site of primary tumor, n (%)

 Colon

593 (61.5)

398 (60.5)

0.679

 Rectum

371 (38.5)

260 (39.5)

 

PS at 1st line treatment initiation*, n (%)

 PS 0

378 (52.2)

264 (51.5)

0.811

 PS 1

333 (46.0)

242 (47.2)

 

 PS 2 or PS 3

13 (1.8)

7 (1.4)

 

Adjuvant chemotherapy**, n (%)

317 (32.9)

189 (28.7)

0.081

Resectability of metastases*

 Unresectable

543 (76.5)

374 (75.7)

0.695

 Potentially resectable

127 (17.9)

96 (19.4)

 

 Resectable

40 (5.6)

24 (4.9)

 

Sites of metastases at the time of the initiation of fist-line treatment*, n (%)

 Liver

518 (67.7)

350 (64.0)

0.174

 Lymph nodes

235 (30.7)

143 (26.1)

0.073

 Lungs

182 (23.8)

175 (32.0)

0.001

 Peritoneum

137 (17.9)

111 (20.3)

0.284

 Other localization

116 (15.2)

78 (14.3)

0.693

 2 and more metastasis

338 (44.2)

238 (43.5)

0.822

Bevacizumab regimen in first-line treatment, n (%)

 5 mg/kg every 2 weeks

613 (63.6)

436 (66.3)

0.290

 7.5 mg/kg every 3 weeks

351 (36.4)

222 (33.7)

 

CT at first-line treatment initiation, n (%)

 FOLFOX

511 (53.0)

366 (55.6)

0.259

 XELOX

295 (30.6)

184 (28.0)

 

 FOLFIRI

107 (11.1)

83 (12.6)

 

 XELIRI

51 (5.3)

25 (3.8)

 

Reason for first-line therapy termination, n (%)

 Disease progression

534 (64.7)

342 (63.0)

0.162

 Surgery

52 (6.3)

47 (8.7)

 

 Adverse event of bevacizumab

48 (5.8)

24 (4.4)

 

 Adverse event of chemotherapy

18 (2.2)

17 (3.1)

 

 Other reason***

173 (17.9)

113 (20.8)

 

Subsequent anti-EGFR-based treatment, n (%)****

 In second line

342 (35.5)

15 (2.3)

-

 In third line

245 (25.4)

8 (1.2)

 

 In fourth line

21 (2.2)

3 (0.5)

 
  1. M, presence of distant metastasis; PS, performance status; *PS data were available for 75% of patients in the wtKRAS subgroup and for 78% patients in the mutant KRAS subgroup. Data on metastasis sites at first-line treatment initiation was available in 79% and 83% of patients, respectively. Data on metastases resectability were available for 74% and 75% patients, respectively. **Adjuvant regimens included FUFA biweekly infusional 5-FU/LV, FOLFOX, capecitabine, and not specified adjuvant CT. ***Other reason for first-line therapy termination included lack of data availability, CR, patient refusal, and death. ****The regimen with anti-EGFR antibodies were following: FOLFOX4+ panitumumab, FOLFIRI + panitumumab, FOLFOX4 + cetuximab, FOLFIRI + cetuximab, irinotecan (250 mg/m2 IV every 2 weeks) + cetuximab, panitumumab or cetuximab as single agents. Schedules and dosage of chemotherapy was identical to those applied in the first-line treatment. Panitumumab was administered 6 mg/kg IV every 2 weeks, cetuximab was administered 500 mg/m2 IV every 2 weeks or 400 mg/m2 IV first infusion, then 250 mg/m2 IV weekly. The registry did not provide reliable data on number of patients treated subsequently with chemotherapy alone. The chemotherapeutic regimen applied without addition of anti-EGFR antibodies were FOLFOX, FOLFIRI, XELOX or XELIRI as defined in Methods section.
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us